VDP Stake Raised to 11.5% by Individual Investor as Vidipha Rights Issue Looms

Overview

Nguyen Quoc Hung, an individual investor, has become a major shareholder of CTCP Dược phẩm Trung ương Vidipha (VDP) after purchasing over 2.5 million shares on August 12, 2026. The transaction, valued at nearly VND 101.5 billion, increased his stake from 0% to 11.545%. This development coincides with Vidipha’s ongoing rights issue aimed at funding a new production line.

Key Facts

• Nguyen Quoc Hung bought 2,500,000+ VDP shares on August 12, 2026, raising his ownership to 11.545%.
• The transaction was executed as a negotiated deal on HOSE with a value of nearly VND 101.5 billion.
• Another individual investor, Le Quang Hai, purchased over 4.95 million VDP shares on August 7, 2026, increasing his stake to 22.503%.
• Vidipha is conducting a rights issue of nearly 9.94 million shares at a ratio of 100:45, with a subscription price of VND 10,000 per share.
• The rights issue is expected to raise over VND 99.3 billion, with the record date set for July 24, 2026.
• Proceeds will fund a new cephalosporin powder injection production line with a total investment of VND 127.8 billion, targeting EU-GMP standards.
• The new production line is scheduled to be operational from January 2028, with a designed capacity of 10 million vials per year.

What Happened

According to a filing with HOSE, Nguyen Quoc Hung reported becoming a major shareholder of Vidipha after purchasing over 2.5 million VDP shares on August 12, 2026. The negotiated transaction, valued at nearly VND 101.5 billion, increased his stake from zero to 11.545%. This follows a similar move by Le Quang Hai, who acquired over 4.95 million shares on August 7, 2026, raising his ownership to 22.503%.

Vidipha is currently in the middle of a rights issue to existing shareholders, offering nearly 9.94 million shares at a ratio of 100:45. The subscription period runs from August 5 to August 26, 2026, with rights transferable once. If fully subscribed, the company’s charter capital will increase from VND 220.8 billion to over VND 320.2 billion. The proceeds, over VND 99.3 billion, will be used to invest in a new cephalosporin powder injection production line meeting EU-GMP standards. The project, with a total investment of VND 127.8 billion, includes VND 2 billion for factory renovation and VND 97.2 billion for machinery and equipment.

Market Context

VDP shares closed at VND 39,000 on August 13, 2026, on HOSE. The recent accumulation by two individual investors, who together now hold over 34% of the company, suggests growing interest in the stock. This comes amid the company’s expansion plans and the broader Vietnamese pharmaceutical sector’s focus on upgrading manufacturing standards to EU-GMP. The rights issue, priced at VND 10,000 per share, represents a significant discount to the current market price, potentially attracting further investor attention.

Strategic Significance

The entry of major shareholders and the ongoing rights issue signal a period of transformation for Vidipha. The new production line, targeting EU-GMP standards, positions the company to compete in higher-value pharmaceutical segments, potentially expanding its market reach. For long-term investors, the successful execution of the rights issue and the completion of the production line by 2028 could enhance Vidipha’s revenue and profitability. However, the concentration of ownership among a few individuals may also raise governance considerations.

What to Watch

• Completion of the rights issue subscription by August 26, 2026, and the final capital increase.
• Further stake changes by major shareholders, including Nguyen Quoc Hung and Le Quang Hai, in the coming months.
• Progress on the cephalosporin production line construction, with operational target set for January 2028.
• Quarterly earnings reports to assess the impact of the new investments on financial performance.
• Any regulatory approvals or updates regarding EU-GMP certification for the new facility.